Upgrade to SI Premium - Free Trial

Ultragenyx agrees to sell rare pediatric disease PRV for $203M

October 14, 2026 8:30 AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Mergers and Acquisitions